Literature DB >> 2174895

Cytofluorimetric analysis of mitogen-activated peripheral blood lymphocytes of non-leukemic lymphoma patients reveals an abnormal disease-related expression pattern of activation antigens.

H Mangge1, F Beaufort, W Kaulfersch, E Rossipal, K Schauenstein.   

Abstract

The purpose of this study was to examine patterns of peripheral T-cell-activation antigen expression after polyclonal in vitro stimulation in early stages of lymphoproliferative diseases. With 18 patients afflicted with recently diagnosed, non-leukemic stages of B and T cell lymphoma cytofluorimetric analysis was performed with peripheral blood lymphocytes (PBL) after 72 h in culture with and without phytohemagglutinin, using antibodies against the differentiation antigens CD3, CD8, CD4, CD16, CD19, CDw14, and the activation antigens interleukin-2 receptor (IL-2R, CD25), HLA-DR (DR), CD56 and transferrin receptor (TR). Compared to healthy controls and patients with other diseases, a very significant reduction of large T cells bearing activation markers was found in all lymphoma cases. Furthermore, a pronounced inhibition in the expression of the activation markers IL-2R and TR, but not of DR, was detected on CD3+ cells in phytohemagglutinin-stimulated PBL of all lymphoma cells independently of DNA synthesis, as measured by [3H]thymidine uptake. Determination of the natural-killer-cell-(NK)-associated antigens CD16 and CD56, available for our studies in a CD16 + CD56 combination kit, revealed, after phytohemagglutinin stimulation, significantly increased expression values in 8 lymphoma patients so far investigated, as compared to 12 healthy controls. Thus, polyclonal activation combined with cytofluorimetric screening of activation antigens seems to give useful information on the functional defect(s) of PBL in an early state of lymphoma, and may therefore be of considerable diagnostic value. The observed pattern of T cell activation antigen expression after phytohemagglutinin stimulation may give further clues to the understanding of immune dysfunction(s) associated with lymphoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174895     DOI: 10.1007/BF01637077

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  32 in total

1.  A new micromethod for lymphocyte stimulation using whole blood.

Authors:  J Eskola; E Soppi; M Viljanen; O Ruuskanen
Journal:  Immunol Commun       Date:  1975

2.  Unusual prevalence of Epstein-Barr virus early antigen (EBV-EA) antibodies in ataxia telangiectasia.

Authors:  J Joncas; N Lapointe; F Gervais; M Leyritz
Journal:  J Immunol       Date:  1977-11       Impact factor: 5.422

3.  Whole blood microculture assay of human lymphocyte function.

Authors:  J L Pauly; T Han
Journal:  J Lab Clin Med       Date:  1976-11

4.  Zinc and anergy in pediatric Hodgkin's disease in Turkey.

Authors:  A O Cavdar; E Babacan; S Gözdaşoğlu; J Erten; S Cin; A Arcasoy; U Ertem
Journal:  Cancer       Date:  1987-01-15       Impact factor: 6.860

5.  Peripheral blood lymphocyte response to recombinant and non-recombinant interleukin 2 in previously treated patients with Hodgkin's disease, long-time off-therapy.

Authors:  G Mantovani; A Coiana; A Massidda; F Locci; M Loy; G Piludu; M C Piras; A Macciò; G S Del Giacco
Journal:  Eur J Haematol       Date:  1987-02       Impact factor: 2.997

6.  Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity.

Authors:  J Passwell; M Levanon; J Davidsohn; B Ramot
Journal:  Clin Exp Immunol       Date:  1983-01       Impact factor: 4.330

7.  Malignant lymphoma in a renal transplant patient on cyclosporin A therapy.

Authors:  R J Walker; D J Tiller; J S Horvath; G G Duggin
Journal:  Aust N Z J Med       Date:  1989-04

8.  Prostaglandin-related and adherent cell suppressor system in apparently cured Hodgkin's disease patients.

Authors:  N Haim; A Meidav; B Samuelly; R Segal; T Mekori; E Robinson
Journal:  J Biol Response Mod       Date:  1984

9.  Association of an interleukin abnormality with the T cell defect in Hodgkin's disease.

Authors:  R J Ford; J Tsao; N M Kouttab; C G Sahasrabuddhe; S R Mehta
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

10.  Clonal ambiguity of human immunodeficiency virus-associated lymphomas. Similarity to posttransplant lymphomas.

Authors:  S M Lippman; J R Volk; C M Spier; T M Grogan
Journal:  Arch Pathol Lab Med       Date:  1988-02       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.